160 related articles for article (PubMed ID: 33822517)
1. SET Domain-Containing Protein 5 Enhances the Cell Stemness of Non-Small Cell Lung Cancer via the PI3K/Akt/mTOR Pathway.
Chen Q; Sun Z; Li J; Zhang D; Guo B; Zhang T
J Environ Pathol Toxicol Oncol; 2021; 40(2):55-63. PubMed ID: 33822517
[TBL] [Abstract][Full Text] [Related]
2. SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.
Yu H; Sun J; Zhao C; Wang H; Liu Y; Xiong J; Chang J; Wang M; Wang W; Ye D; Zhou H; Yu T
BMC Cancer; 2019 Jul; 19(1):736. PubMed ID: 31345185
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of SETD5 Inhibits Colorectal Cancer Cell Growth and Stemness by Regulating PI3K/AKT/mTOR Pathway.
Zhou X; Chen W; Zhuang D; Xu G; Puyang Y; Rui H
Biochem Genet; 2024 Apr; ():. PubMed ID: 38641699
[TBL] [Abstract][Full Text] [Related]
4. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway.
Liang Z; Zhong Y; Meng L; Chen Y; Liu Y; Wu A; Li X; Wang M
Thorac Cancer; 2020 Nov; 11(11):3155-3167. PubMed ID: 32926529
[TBL] [Abstract][Full Text] [Related]
5. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
8. LAGE3 promotes cell metastasis and stemness in non-small cell lung cancer companied with AKT/PI3K signaling pathway activation.
Zhang H; Jian J; Chen H; Zhu X; Xie J; Xu X
Pathol Res Pract; 2023 Aug; 248():154700. PubMed ID: 37473499
[TBL] [Abstract][Full Text] [Related]
9. SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness.
Piao L; Li H; Feng Y; Yang Z; Kim S; Xuan Y
Exp Cell Res; 2020 Apr; 389(1):111861. PubMed ID: 31981592
[TBL] [Abstract][Full Text] [Related]
10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway.
Yiyan S; Yang S; Li D; Li W
Curr Cancer Drug Targets; 2022; 22(1):86-95. PubMed ID: 34325639
[TBL] [Abstract][Full Text] [Related]
12. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
Jiang M; Zhou LY; Xu N; An Q
Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
[TBL] [Abstract][Full Text] [Related]
13. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
14. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
15. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.
Lv J; Liu C; Chen FK; Feng ZP; Jia L; Liu PJ; Yang ZX; Hou F; Deng ZY
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184083
[TBL] [Abstract][Full Text] [Related]
16. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer.
Schaal CM; Bora-Singhal N; Kumar DM; Chellappan SP
Mol Cancer; 2018 Oct; 17(1):149. PubMed ID: 30322398
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway.
Zhu Q; Liang X; Dai J; Guan X
Int J Clin Exp Pathol; 2015; 8(8):9175-81. PubMed ID: 26464663
[TBL] [Abstract][Full Text] [Related]
19. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway.
Lv X; Li CY; Han P; Xu XY
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2321-2327. PubMed ID: 29762835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
